Results 261 to 270 of about 808,049 (434)

Longitudinal Trajectories of Digital Cognitive Biomarkers for Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, Volume 12, Issue 4, Page 842-850, April 2025.
ABSTRACT Background Cognitive impairment is one of the most common and debilitating symptoms of relapsing–remitting multiple sclerosis (RRMS). Digital cognitive biomarkers require less time and resources and are rapidly gaining popularity in clinical settings.
Yi Chao Foong   +17 more
wiley   +1 more source

Incremental payments for consultants [PDF]

open access: green, 1976
N. Jones   +17 more
openalex   +1 more source

Claustrum Volume Is Reduced in Multiple Sclerosis and Predicts Disability

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The claustrum is a small, thin structure of predominantly gray matter with broad connectivity and enigmatic function. Little is known regarding the impact of claustrum pathology in multiple sclerosis (MS). Methods This study assessed whether claustrum volume was reduced in MS and whether reductions were associated with specific ...
Nicole Shelley   +5 more
wiley   +1 more source

Exploring gender differences in the working lives of UK hospital consultants

open access: yesJournal of the Royal Society of Medicine, 2015
L. Jefferson, K. Bloor, K. Spilsbury
semanticscholar   +1 more source

Diagnostic Challenge in Frontal Variant Alzheimer's Disease With Low Amyloid‐β PET Retention

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Diagnosing frontal variant Alzheimer's disease (fvAD) is difficult and could be even more difficult when amyloid‐beta (Aβ) PET retention is low. A 63‐year‐old woman presenting with a 3‐year history of apathy and memory impairment showed executive dysfunction, memory impairment, and severe bilateral frontotemporal atrophy on MRI.
Ryosuke Shimasaki   +5 more
wiley   +1 more source

Psychosocial screening instruments to assist support consultants in patients with cancer. [PDF]

open access: yesBMJ Support Palliat Care
Driessen HPA   +4 more
europepmc   +1 more source

Phase 1, First‐In‐Human, Single‐/Multiple‐Ascending Dose Study of Iluzanebart in Healthy Volunteers

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of iluzanebart, a fully human monoclonal antibody TREM2 (triggering receptor expressed on myeloid cells 2) agonist, after single‐ (SAD) and multiple‐ascending‐dose (MAD) administration.
Andreas Meier   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy